23 Aug 2010 07:00
| Press Release | 23 August 2010 |
LIDCO GROUP PLC
("LiDCO" or the "Company")
Issue of Equity
LiDCO (AIM:LID), the cardiovascular monitoring company, announces that application has been made for 42,500 ordinary shares of 0.5 pence each in the Company ("Ordinary Shares") to be admitted to trading on the AIM Market of the London Stock Exchange ("Admission"). The new Ordinary Shares are being issued pursuant to the exercise of an option by a former employee.
The new Ordinary Shares rank pari passu with the Company's existing Ordinary Shares and admission is expected to become effective on 25 August 2010.
Following Admission, the Company will have 173,984,054 Ordinary Shares in issue with each share carrying the right to one vote.
There are no shares held in Treasury.
The total number of voting rights in LiDCO is therefore 173,984,054. This number may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, Intercede, under the Disclosure and Transparency Rules.
- Ends -
For further information, please contact:
| LiDCO Group Plc |
|
| Terry O'Brien (CEO) | Tel: +44 (0)20 7749 1500 |
| Paul Clifford (Finance Director) |
|
| John Rowland (Company Secretary) | www.lidco.com |
| FinnCap |
|
| Geoff Nash / Marc Young Stephen Norcross (broking) | Tel: +44 (0)20 7600 1658 www.finncap.com |
Media enquiries:
| Abchurch |
|
| Heather Salmond / Joanne Shears/ Simone Elviss | Tel: +44 (0) 20 7398 7709 |
| simone.elviss@abchurch-group.com | www.abchurch-group.com |
About LiDCO Group Plc
LiDCO is a supplier of minimally invasive hemodynamic monitoring equipment and disposables to hospitals. These products are used primarily for the management of adult hospital patients requiring critical care or at major cardiovascular risk. LiDCO's computer-based technology can significantly reduce the complications (particularly infections) and costs associated with major surgery. The technology was invented in the Department of Applied Physiology based at St Thomas' Hospital, London. LiDCO is based in the UK and its shares are traded on AIM. For more information please see www.lidco.com.
The Company's sales office is in Cambridge, its manufacturing facility / general administration base is in Hoxton, London, and its current products are:
* LiDCOplus is a computer-based platform monitor used in the Intensive Care Unit for real-time continuous display of hemodynamic parameters including cardiac output, oxygen delivery and fluid-volume responsiveness (PPV% and SVV%)
* LiDCOrapid: our new cardiac output monitor designed specifically for use in the Operating Theatre for fluid and drug management. The monitor enables acute-care physicians to get accurate and immediate feedback on the patient's fluid and hemodynamic status - a key measure of overall well-being both during and after surgery. These benefits are:
| ·; | Early and rapid warning of change |
| ·; | Clear indication of therapeutic route: fluid or drug |
| ·; | Quantification of hemodynamic response, particularly stroke volume |
| ·; | Permits more effective delivery of fluids - the right amount at the right time |
| ·; | Advanced hemodynamic care has been shown to contribute to: - Reduced morbidity and complications, length of stay & overall cost of care |
* LiDCO single-patient-use disposables used in conjunction with the LiDCOplus and LiDCOrapid.
* LiDCOview:an easy-to-use graphical display of historical LiDCOplus and LiDCOrapid hemodynamic data.
* LiDCO's Distribution Network:
The Company sells via its own direct sales force to hospitals in the UK, and in export markets predominantly through a worldwide network of speciality critical care and anesthesia distributors.